[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2020 Feb 26

PMID 32093454

Citations 9

Authors

Hanfei Guo

Rilan Bai

Jiuwei Cui

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) therapy is the most commonly used immunotherapy regimen at present. It has been approved for clinical treatment of melanoma, kidney cancer, head and neck cancer, bladder cancer and other tumors. It has made a breakthrough in the treatment of lung cancer and become a new pillar of comprehensive treatment of lung cancer. However, ICIs alone is less effective in non-selective patients, and combination therapy has become a hot topic of exploration. This article focuses on the development of combined immune checkpoint inhibitors and describes how immunotherapy can be used to treat early stage cancer.

Citing Articles

Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.

Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, Zokirova F Ther Adv Vaccines Immunother. 2024; 12:25151355241305856.

PMID: 39691280 PMC: 11650588. DOI: 10.1177/25151355241305856.

Decoding the Ferroptosis-Related Gene Signatures and Immune Infiltration Patterns in Ovarian Cancer: Bioinformatic Prediction Integrated with Experimental Validation.

Zhang B, Guo B, Kong H, Yang L, Yan H, Liu J J Inflamm Res. 2024; 17:10333-10346.

PMID: 39654865 PMC: 11626233. DOI: 10.2147/JIR.S498740.

Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.

Jia W, Yu H, Song L, Wang J, Niu S, Zang G Front Med (Lausanne). 2023; 10:1239351.

PMID: 38034540 PMC: 10687557. DOI: 10.3389/fmed.2023.1239351.

Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.

He M, Zhang D, Cao Y, Chi C, Zeng Z, Yang X Heliyon. 2023; 9(8):e19147.

PMID: 37664750 PMC: 10469587. DOI: 10.1016/j.heliyon.2023.e19147.

Baci D, Cekani E, Imperatori A, Ribatti D, Mortara L Front Immunol. 2022; 13:914890.

PMID: 35874749 PMC: 9298844. DOI: 10.3389/fimmu.2022.914890.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Lee J, Cimino-Mathews A, Peer C, Zimmer A, Lipkowitz S, Annunziata C . Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A.... J Clin Oncol. 2017; 35(19):2193-2202. PMC: 5493052. DOI: 10.1200/JCO.2016.72.1340. View

Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R . The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007; 220:47-59. DOI: 10.1111/j.1600-065X.2007.00573.x. View

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F . Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clin Cancer Res. 2017; 24(2):407-419. DOI: 10.1158/1078-0432.CCR-17-2156. View

Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A . 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010; 70(8):3052-61. DOI: 10.1158/0008-5472.CAN-09-3690. View

Konstantinopoulos P, Waggoner S, Vidal G, Mita M, Moroney J, Holloway R . Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019; 5(8):1141-1149. PMC: 6567832. DOI: 10.1001/jamaoncol.2019.1048. View

Bommareddy P, Shettigar M, Kaufman H . Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018; 18(8):498-513. DOI: 10.1038/s41577-018-0014-6. View

Restifo N, Smyth M, Snyder A . Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016; 16(2):121-6. PMC: 6330026. DOI: 10.1038/nrc.2016.2. View

10.

Theelen W, Peulen H, Lalezari F, van der Noort V, de Vries J, Aerts J . Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9):1276-1282. PMC: 6624814. DOI: 10.1001/jamaoncol.2019.1478. View

11.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

12.

Vacchelli E, Ma Y, Baracco E, Sistigu A, Enot D, Pietrocola F . Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015; 350(6263):972-8. DOI: 10.1126/science.aad0779. View

13.

Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018; 19(5):694-704. PMC: 6089612. DOI: 10.1016/S1470-2045(18)30148-7. View

14.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

15.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

16.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

17.

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa M, Belsue V . Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019; 569(7756):428-432. DOI: 10.1038/s41586-019-1162-y. View

18.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J . PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23(14):3711-3720. PMC: 5511572. DOI: 10.1158/1078-0432.CCR-16-3215. View

19.

Dovedi S, Illidge T . The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology. 2015; 4(7):e1016709. PMC: 4485833. DOI: 10.1080/2162402X.2015.1016709. View

20.

Oshima Y, Tanimoto T, Yuji K, Tojo A . EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(8):1112-1115. PMC: 5885195. DOI: 10.1001/jamaoncol.2017.4526. View